Melanotan-II (MT-2) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It is a broad melanocortin-receptor agonist used in research as a tool for studying the melanocortin system in model systems, especially receptors linked to pigmentation research.
Broad melanocortin agonism
Unlike the more MC4R-focused PT-141, melanotan-II engages multiple melanocortin receptors including MC1R, which is central to melanin-related research endpoints. This breadth is the defining feature of its research profile and the pathway is detailed in its mechanism of action.
Structure
Its cyclic lactam design confers stability relative to native α-MSH, allowing it to persist in assay conditions. The structural rationale is described in its chemistry and synthesis article, and the principles of reading such modified sequences are in understanding amino acid sequences.
Origin
MT-2 emerged from melanocortin-system research seeking durable α-MSH analogs; the full account is in its discovery and history.
Research context
PT-141 is a related melanocortin compound derived from the same broad scaffold, so the two are frequently studied together to separate receptor-subtype effects. Documented purity underpins reproducible work — see understanding HPLC purity. All findings here describe research-model behavior only, with no cosmetic or applied claims.
Use as a reference agonist
MT-2 is most informative when a study needs a stable, broad melanocortin agonist as a positive control or comparator. Its lack of subtype selectivity is a feature for system-level screening but a limitation for assigning a response to one receptor. Selective antagonists or single-receptor expression models are needed for that purpose.
Pigmentation-research framing
In pigmentation-oriented models, researchers may measure MC1R-linked cAMP signaling, melanogenic pathway markers, or pigment-related cellular readouts. Such observations remain properties of the experimental system and do not establish cosmetic or human-use outcomes. Model species, receptor expression, assay timing, and compound integrity all influence the result.
Experimental design
Experimental design should pair MT-2 with vehicle controls and, where possible, subtype-selective pharmacological or genetic tools. Orthogonal measurements, such as a proximal signaling assay plus a later pathway marker, help test whether a pigmentation-model response follows the expected receptor cascade. Broad agonism also means that receptor expression outside the intended target must be considered in mixed-cell or tissue preparations. Reporting receptor profiles and assay sensitivity adds context for comparison.
Product page: Melanotan-II (MT-2) research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.